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wnloadepose: To compare clinical, immunohistochemical (IHC), and gene expression models of prognosis
able to formalin-fixed, paraffin-embedded blocks in a large series of estrogen receptor (ER)–positive
cancers from patients uniformly treated with adjuvant tamoxifen.
erimental Design: Quantitative real-time reverse transcription-PCR (qRT-PCR) assays for 50 genes
fying intrinsic breast cancer subtypes were completed on 786 specimens linked to clinical (median
-up, 11.7 years) and IHC [ER, progesterone receptor (PR), HER2, and Ki67] data. Performance of
fined intrinsic subtype and risk-of-relapse scores was assessed using multivariable Cox models and
n-Meier analysis. Harrell's C-index was used to compare fixed models trained in independent data
ncluding proliferation signatures.
ults: Despite clinical ER positivity, 10% of cases were assigned to nonluminal subtypes. qRT-PCR
ures for proliferation genes gave more prognostic information than clinical assays for hormone re-
s or Ki67. In Cox models incorporating standard prognostic variables, hazard ratios for breast can-
sease-specific survival over the first 5 years of follow-up, relative to the most common luminal A
e, are 1.99 [95% confidence interval (CI), 1.09-3.64] for luminal B, 3.65 (95% CI, 1.64-8.16) for
-enriched subtype, and 17.71 (95% CI, 1.71-183.33) for the basal-like subtype. For node-negative
e, PAM50 qRT-PCR–based risk assignment weighted for tumor size and proliferation identifies a
with >95% 10-year survival without chemotherapy. In node-positive disease, PAM50-based prog-
models were also superior.
clusion: The PAM50 gene expression test for intrinsic biological subtype can be applied to largeseries of formalin-fixed, paraffin-embedded breast cancers, and gives more prognostic information than

















ns: 1Genetic Pathology Evaluation Centre, Vancouver
earch Institute, British Columbia Cancer Agency, and
h Columbia, Vancouver, British Columbia, Canada;
ehensive Cancer Center and Departments of Genetics,
Laboratory Medicine, University of North Carolina at
el Hill, North Carolina; 3Department of Pathology,
Health Sciences Center, Salt Lake City, Utah; and
netics, The Genome Center, Washington University
, St Louis, Missouri; 5Department of Medicine, Division
ngtonUniversity School ofMedicine, St Louis,Missouri;
ensive Cancer Center, Washington University School of
es-Jewish Hospital, St Louis, Missouri
ry data for this article are available at Clinical Cancer
ttp://clincancerres.aacrjournals.org/).
uthor: Torsten O. Nielsen, Department of Pathology
edicine, University of British Columbia, Anatomical
VancouverHospital, 855West12thAvenue,Vancouver,
anada V5Z 1M9. Phone: 604-875-4111-66768; Fax:
ail: torsten@interchange.ubc.ca.
0432.CCR-10-1282
ssociation for Cancer Research.
; 16(21) November 1, 2010
Research. 
on February 27, clincancerres.aacrjournals.org d from eral gene expression technologies and statistical
ls have reported methodologies to identify breast
r patients with estrogen receptor–positive (ER+),
negative (N0) disease that may be adequately man-
ith 5 years of tamoxifen monotherapy (1–5). How-
these studies often included patients with tumors
y associated with established low-risk biomarkers,
ample, low-grade histology, low Ki67-based prolifer-
index, and favorable surgical stage. It therefore re-
controversial whether genomic assays should be
d routinely, or whether surgical stage and a limited
er of immunohistochemical (IHC) markers will, in
cases, be adequate and less costly (6).
clinical significance of continued efforts in this ar-
elevant for decisions about both chemotherapy and
rine agents, as patients at low risk after 5 years of
ifen monotherapy could be spared the morbidity




















































































Molecular intrinsic subtyping reveals the major bi-
ological categories of breast cancer. Herein, we show
adaptation of a 50-gene intrinsic subtyping signature
for testing standard paraffin blocks. Using a large, ho-
mogeneously treated cohort of breast cancer patients,
we directly compare gene expression results with
high-quality clinical and central immunohistochemi-
cal data. We show the PAM50 approach to be supe-
rior as a prognostic test, specifically able to identify
an ultralow-risk group who may not need chemother-
apy. Based on these results, intrinsic subtyping tests
are now being applied to randomized clinical trials
series in Canada and the United States to assess pre-
dictive capacity (already under way for response to
endocrine therapy, anthracyclines, and taxanes, with
further studies under consideration). Should such
studies prove a predictive value for intrinsic subtyp-
ing, this test could be clinically implemented in a




Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-1282 ated with extended aromatase inhibitor therapy (7).
s that address this issue are few because extremely
ollow-up and information on breast cancer–specific
lity are required. Furthermore, because frozen tu-
rchives are unavailable from suitably large patient
ations, gene expression technologies must be appli-
to degraded RNA extracted from formalin-fixed,
in-embedded tissues that are necessarily more than
de old.
r group has assembled and published several techno-
l and statistical approaches to address prognosis in
reast cancer. We therefore sought to compare clinico-
logic, IHC, and molecular methodologies in a single
endent test set to identify the best approach. Impor-
, we focused on fixed statistical models that were
usly trained on independent data sets to avoid over-
istic results. The models we report in this article in-
the use of standard pathologic factors, such as
lly reviewed histologic grade, as incorporated into
ant! Online (8), models based on IHC for biomar-
f intrinsic subtypes (6), and a gene expression assay
50 genes (PAM50). The latter represents a reduced
et, amenable to assay by techniques such as quanti-
real-time reverse transcription-PCR (qRT-PCR),
accurately identifies the major intrinsic biological
pes of breast cancer and generates risk-of-relapse
) scores (9). The investigation used a large indepen-
ohort of formalin-fixed, paraffin-embedded pathol-
+
tandard laboratory specimens.ecimens from patients with ER breast cancer, all
ut otherwise representing a spectrum of T and N
including a large fraction of node-positive (N+)







on February 27, clincancerres.aacrjournals.org wnloaded from s of tamoxifen therapy but no adjuvant chemother-
nd were followed for relapse-free survival (RFS) and
e-specific survival (DSS) for over a decade.
rials and Methods
t and sample characteristics
study cohort was accrued from female patients with
ve breast cancer, diagnosed in British Columbia be-
1986 and 1992. Cancer tissue from these patients
een frozen and shipped to Vancouver Hospital for
al ER and progesterone receptor (PR) testing by
n-charcoal–coated (DCC) ligand-binding assay. The
0 assay was conducted on the portion of this tissue
as formalin fixed and paraffin embedded for histo-
correlation. Characteristics of this cohort have been
usly described (6), and the same source blocks were
to assemble tissue microarrays for previously pub-
studies on ER (10), HER2 (11), PR (12), Ki67, cyto-
n 5/6, and epidermal growth factor receptor (6, 13).
titative ER was determined using the Ariol automated
l imaging system (14), and the same method was ap-
for PR. For this study, we selected samples from
ts with ER+ tumors by IHC who had received tamox-
s their only adjuvant systemic therapy. Provincial
lines from that time period recommended tamoxifen
men >50 years of age, whose ER status was positive or
wn, and who were either node positive or had lym-
scular invasion. Cohort identification and sample
ion for this study are summarized as per REMARK
a (15) in Supplementary Table S1.
preparation, qRT-PCR, and assignment of
gical subtype and ROR score
E sections from each block were reviewed by a pa-
gist (T.O.N.). Areas containing representative inva-
reast carcinoma were selected and circled on the
block. Using a 1.0-mm punch needle, at least two
r cores were extracted from the circled area. Details of
preparation from paraffin cores, the qRT-PCR assay
e PAM50 panel and reference genes, and how these
s allow assignment into luminal A, luminal B, HER2-
ed, and basal-like subtypes, and the independently
d ROR-S (ROR based on subtype), ROR-T (ROR
on tumor size weighted model), ROR-P (ROR based
oliferation weighted model), and ROR-PT (ROR
on proliferation and tumor size weighted) risk score
ments are presented in Supplementary Materials and
ds. For clarity, the term ROR-T is now used for the
model described in our earlier publication as ROR-C
ical”; ref. 9).
ion of clinicopathologic factors, intrinsic
pes, and ROR scores to clinical outcome
PAM50 in ER-Positive Breast Cancertistical analyses were conducted using SPSS v16.0
v2.8.0. Univariable analyses of tumor subtype
t breast cancer RFS and DSS were done by Kaplan-
analysis with log-rank test. Multivariable analyses
Clin Cancer Res; 16(21) November 1, 2010 5223










































































Positive (>10 fmol/mg) 768
Median (fmol/mg) 254.
(Continued on
cer Res; 16(21) November 1, 2010
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for Cancer1. Clinical characteri tics of the whole co rtl parameter To l
LumPA
al A Lum50 subtype
al B HEll N = 786)













-up-times in Median 1 1 8 5 14(min-max) (0.55 8) (0.5 18) (0.6 18) (0.55 8) (1.6- 6) (3.2- )) Median 6 6 6 66 65 68
Yes 2 1 2 1 0
No 75 35 31 6 4 14Un nown/pregnant 1 0 0 2
lete mastectomy 46 21 20 3 5 11Pa ial mastectomy 30 15 11 2 0 5
Other 1 2 0 0node dissection Yes 74 34 31 6 5 16
No 4 2 1 2 0 0
Yes 41 20 16 4 1 7
No 36 16 16 2 4 9Median .0 .5 3 2
T0/IS 1 0 0 1
T1 33 18 11 2 3 3
T2 38 16 17 2 2 6
T3 1 3 0 1
T4 3 1 1 3 0 4
TX 2 1 3 0 1
0 22 9 9 1 1 10
1-3 36
4-9 1218 14 2 1 310+ 2
Unknown 51 1 2 0 0rade 1: well
ifferentiated
3 2 1 1 2e 2: moderately 33 18 12 1 0 9
ifferentiated
ade 3: poorly 37 13 17 4 3 5
ifferentiated
Unknown 4 2 1 1 1 0
uctal NOS 70 32 30 6 4 13
Lobular 6 3 2 4 1 3Mucinous 7 0 0 0
Tubular 7 0 0 0
Medullary 2 0 0 0ovascular invasion
Apocrine 1 0 0 0Yes 48 21 22 4 2 9
No 26 13 9 1 3 7Unknown 3 2 1 1 0 0
l ER status (DCC
d-binding assay)
Missing 9 5 3 0 0 1
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Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-1282 one against the standard clinical parameters of tu-
ize, nodal status, histologic grade, patient age, and
status. HER2 scores were centrally determined
on assay of adjacent cores from the same source
, assembled into tissue microarrays, and subjected
Unknown 15
reviation: NOS, not otherwise specified.C and fluorescence in situ hybridization (FISH)
is using clinical-equivalent protocols (11). Cox re-
n models (16) were built to estimate the
d ratios of the qRT-PCR–assigned brea
on th
used
tion of each curve. B and D, breast




on February 27, clincancerres.aacrjournals.org wnloaded from pes, as well as ROR scores categorized by pub-
cut points and as a continuous variable. IHC-
subtypes were assigned as previously defined
he online decision-making tool Adjuvant! Online
//www.adjuvantonline.com), previously validated
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for Cancer1. Clinical characteri
l parametertics of the whole co rt (Cont' )To l PA 50 subtype ll N = 786)Lum al A Lum al B HE 2 Bas l Norm ll PR status (DCC
d-binding assay) NegaMissing 16 8 1
ive (0-9 fmol/mg) 7 1 1
ive (>10 fmol/mg) 55 27 2 3Median (fmol/mg) 129 202 84.5 17 153 239
HER2 with FISH
orrection on 2+ cases
Negative 696 348 294 34 4 16
Positive 75 15 30 29 1 0was
atesadjusted
st cancer
for each patient in this cohort. Only cases with informa-
tion for all the covariates were included in the analyses.Kaplan-Meier survival analysis of
subtype (A and B) and ROR-S (C and
etermined by PAM50 gene expression
ement by qRT-PCR done on paraffin
from women with invasive breast
ma, treated with adjuvant tamoxifen.
mber of events and total number of

















































































































Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-1282 thed plots of weighted Schoenfeld residuals were
to assess proportional hazard assumptions (17),
ime stratifications were used where hazards were
roportional over the entire follow-up period.
C-index (concordance index; ref. 18) is defined as the
bility that risk assignments to members of a random
re accurately ranked according to their prognosis. The
er of concordant pairs (order of failure and risk as-
ent agree), discordant pairs (order of failure and risk
ment disagree), and uninformative pairs are tabulat-
calculate the measure. C-index values of 0.5 indicate
m prediction, and higher values indicate increasing
tion accuracy. Variability in the C-index for each pre-
and P values from comparisons were estimated from
bootstrap samples of the risk assignments. Calcula-
as done using the rcorr.cens function implemented
Hmisc (19) library for R statistical software version
(http://www.R-project.org).
lts
sic subtyping of ER+, tamoxifen-treated breast
r using the PAM50 assay
was extracted from pathologist-guided tissue cores
991 formalin-fixed, paraffin-embedded breast cancer
ens. Eight hundred and eleven samples yielded
ent RNA for analysis (at least 1.2 μg total RNA at a
ntration of ≥25 ng/μL). Template was technically suf-
in 786 cases, based on all internal housekeeper gene
ls being expressed in the sample above background.
al characteristics for the patients included in the
0 analysis are presented in Table 1 (Supplementary
S2 and S3 provide details stratified by node status).
on the nearest PAM50 centroid algorithm, intrinsic
cancer subtypes were assigned using gene expression
lows: 372 samples (47.3%) were luminal A, 329
) luminal B, 64 (8.1%) HER2 enriched, 5 (0.6%)
like, and 16 (2.0%) normal-like. Thus, although
ses in this study were positive for ER by centrally
ed IHC analysis on a tissue microarray (10), and
were also positive by DCC biochemical assay
1), the gene expression panel nevertheless as-
9% of cases into nonluminal subtypes, mostly
enriched. This phenomenon has been previously
ed when interrogating published data sets for ex-
on of the PAM50 genes (9). For the 16 cases as-
as normal-like, histology was reviewed from
nt tissue cores, and in 14 of 16 cases, invasive
cells were absent or rare. Normal-like cases were
ore excluded from outcome analyses, as a breast
subtype could not be confidently assigned due
ufficient tumor content.
intrinsic biological subtypes were strongly prognos-
Kaplan-Meier analysis (Fig. 1A and B). In the British
n et al.bia population at the time these samples were orig-
acquired, many patients with a clinically low-risk
e received no adjuvant systemic therapy (8). In con-
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on February 27, clincancerres.aacrjournals.org wnloaded from tudy) had tumors that were mostly node positive
igh grade, exhibited lymphovascular invasion, and
ore constitute a higher-risk group with overall 10-year
f 62% and DSS of 72%. Those assigned by the PAM50
to luminal A status had a significantly better outcome
ear RFS, 74%; DSS, 83%) than luminal B, HER2-
ed, or basal-like tumors (Fig. 1A for RFS and Fig. 1B
S). The ROR algorithms (9) were originally trained
icroarray data from N0 patients who received no
ant systemic therapy, and have not previously been
d to a population homogeneously treated with adju-
amoxifen, nor to a series containing large numbers of
es, nor to the endpoint of DSS. In this data set, ROR-S
del based solely on gene expression) nevertheless
d performance consistent with our previous report
1C and D). Multivariable Cox models were con-
ed to test the independent value of PAM50 subtyping
st standard clinical and pathologic factors including
istologic grade, lymphovascular invasion, HER2
sion, nodal status, and tumor size. To meet propor-
l hazard assumptions, multivariable models were
ed with the time axis split at 5 years (20), as HER2-
ed and basal-like tumors (Fig. 1A and B) and ROR-S
ategory tumors (Fig. 1C and D) had a much higher
rate in the first 5 years than subsequently. The intrinsic
ical subtype and ROR-S remained significant in the
variable models for DSS (Table 2) and RFS (Supple-
ry Table S4), particularly in the first 5 years, as did
logic staging variables (tumor size and node status).
ver, histologic grade, lymphovascular invasion, and
l HER2 status, significant in univariable analysis in
hort, no longer contributed significant independent
ostic information when the multivariable analysis in-
the PAM50 assignments.
arisons between gene expression and clinical
s for hormone receptors and proliferation
case that is ER+ by IHC, additional information about
one receptor expression can be obtained in several
including DCC ligand-binding assay, quantitative
or ER, or equivalent measures of PR. Most published
for breast cancer prognosis in ER+ disease include
r growth rate as one of the parameters in the statistical
l, and this data set was previously assessed in detail for
i67 index (6). The PAM50 qRT-PCR data allow de-
quantitative assessment of the functionality of the es-
response pathway (8-gene luminal signature) as well
oliferation signature based on themean expression of
nes linked to cell cycle progression (trained on pub-
data, as per Supplementary Materials and Methods).
ailability of all these measurements (10) provides
portunity to determine which approach most ac-
ly captures the prognostic effect of estrogen path-
biomarkers and tumor growth rate in a direct
arison (Fig. 2). Given a randomly selected pair
bjects, C-index is the probability that the patient
ed the more extreme risk score actually has a
prognosis. A value of 0.5 indicates discrimination
Clinical Cancer Research




















Table is o , tam
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Age 1.0 .266 1.0 .9786
Gra 1.5 .140 1.0 .8109
Lym 1.0 .942 1.1 .4852













Age 1.0 .267 1.0 .9089
Gra 1.3 .267 1.0 .9588
Lym 0.9 .852 1.1 .4299












Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-1282 s no better than chance prediction, and a value of
icates perfect discrimination of samples. Using the
ex to compare prognostic capacity in this uni-
y tamoxifen-treated cohort, the combination of lu-
l genes measured by the PAM50 yields more
ostic information than other methods of hor-
receptor analysis, but the differences are not sig-
t. Although Ki67 index by IHC seems to outdo
e variables.
reviation: 95% CI, 95% confidence interval.itative ER, the proliferation signature provides the
robust approach for the prediction of both RFS
SS (Fig. 2; Supplementary Table S5). Multivari-







on February 27, clincancerres.aacrjournals.org wnloaded from ontribute significant independent information to
ostic models for either N0 or N+ breast cancer pa-
when information on the proliferation signature
luded (Supplementary Table S6).
arison of fixed models of prognosis in
east cancer
formal model comparisons, data were generated onPAM50 in ER-Positive Breast Cancer2. Cox model multivariable analys f breast cancer DSS among ER+
tors and (A) intrinsic subtype or (ixed approaches, with
the test set: (a) clinic
e, (b) IHC-based (inc
), (c) the ROR-S app
Clin Cance
2018. © 2010 Americaoxifen-treated women,
OR-S, as determined byout any element of traini
al model based on Adjuva
orporating data on Ki67 a
roach based on PAM50 ge
r Res; 16(21) November 1, 20
n Association for Cancerl endpoint Multivariable DSS Multivariable DSS
(0-5 y of follow-up) 5 y to end of follow-up)H d ratio (95% CI) H d ratio (95% CI)insic subtype
2 (0.99-1.05) 0 5 0 (0.98-1.02) 0de (1-2 vs 3) 1 (0.87-2.60) 0 5 5 (0.71-1.56) 0
phovascular invasion 2 (0.58-1.81) 0 1 6 (0.77-1.75) 0
2 (IHC) 0 (0.77-2.91) 0 4 2 (0.40-1.69) 0
e status (0 as reference group) <0 1 0
-3 7 (0.95-4.54) 4 (0.96-2.47)
+ 0 (2.64-12.71) 8 (1.60-4.82)
or size (T1 as reference group) 0 0
2 2 (0.71-2.09) 2 (1.08-2.42)
3 2 (1.50-10.22) 1 (1.78-14.62)
4 1 (0.38-4.50) 2 (1.85-8.74)1.3 4.0
type (luminal A as reference group) 0.0018 0.0381
uminal B 9 (1.09-3.64) 0 (1.13-2.55)
ER2 enriched 5 (1.64-8.16) 2 (0.72-3.18)
asal-like 1 (1.71-183.33) NA
R-S2 (0.99-1.05) 0 6 0 (0.98-1.02) 0
de (1-2 vs 3) 6 (0.79-2.36) 0 4 1 (0.68-1.51) 0
phovascular invasion 5 (0.54-1.66) 0 8 (0.78-1.79) 0
2 (IHC) 6 (0.77-2.77) 0 7 7 (0.43-1.77) 0
ode status (0 as reference group) < 1 0
-3 4 (1.00-4.60) 5 (0.97-2.48)
+ 3 (2.79-13.05) 8 (1.59-4.86)
or size (T1 as reference group) 0 7 0
2 9 (0.70-2.05) 4 (1.10-2.45)
3 4 (1.32-8.43) 9 (1.30-10.46)T 3.3 3.6
T4 0.90 (0.25-3.19) 4.44 (2.01-9.78)
OR-S (low as reference group) <0.0001 0.0388
Med 2.04 (0.89-4.66) 1.86 (1.15-3.00)














































































Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-1282 sion alone, and (d) the proliferation signature alone
s incorporated into the ROR-P risk model using a β
ient weighting for proliferation (described in Supple-
ry Materials and Methods). Adjuvant! Online incor-
s full tumor size staging information; to account for
fluence of tumor size, the biomarkermodels were also
ted by a β coefficient (T) that incorporated the prog-
information associated with T1 status versus higher T
the level of detail available in the independent train-
ts). This approach created IHC-T, ROR-T, and ROR-PT
ls. In addition, the strong independent influence of N
was accounted for by conducting the analysis sepa-
in the N0 and N+ populations. C-index assessments
d superiority of the biomarker models over the pure-
ical Adjuvant! Online model in the N0 population,
he ROR-PT approach providing the most prognostic
ation (Fig. 3A). In multivariable analysis, the addi-
f ROR-P to a model of ROR-S results in a significant
se in explained prognostic variation (RFS, P = 0.0032;
= 0.0015); ROR-PT is also significant after condition-
ROR-S (RFS, P = 0.0023; DFS, P = 0.0015) but not
(RFS, P = 0.12; DFS, P = 0.13). A continuous score
on ROR-PT was generated to translate the data into
ividual RFS and DSS risk assessment tool (Fig. 3B).
n-Meier analysis illustrates the ability of the ROR-PT
l to identify patients who have an extremely high
e (>95%) of remaining disease-free (Fig. 3C) and
eyond 10 years (Fig. 3D). In contrast, our previously
hed IHC model (6) could not identify a group with
ently favorable outcomes that 5 years of tamoxifen
be considered adequate treatment (i.e., <90% 10-
FS; Fig. 3E and F).
n et al.arison of fixed models of prognosis in
east cancer




alized qRT-PCR values across 8- and 11-signature genes, respectively, as descri
ed from 1,000 bootstrap samples. Single asterisk (*) designates significant improv
and-binding assay. Double asterisk (**) designates significant improvement (P < 0
ancer Res; 16(21) November 1, 2010
Research. 
on February 27, clincancerres.aacrjournals.org wnloaded from del; in contrast to N0 disease, the proliferation signa-
dded relatively little information and proliferation
ting (ROR-PT) did not yield a superior model. Adju-
Online performed almost as well, but had the advan-
f incorporating the actual number of involved lymph
. This information was not available in the indepen-
raining sets used to build the ROR models, and so
not be used in the current analysis (which can, how-
erve to train future models incorporating number of
ed lymph nodes). The continuous scoremodel for N+
e (Fig. 4B) produces a very broad range of prognosis,
r to N0 disease, although few patients have a progno-
the range where tamoxifen monotherapy for 5 years
be considered sufficient treatment. Although there
arge and highly significant differences in survival in
defined risk groups, Kaplan-Meier analysis (Fig. 4C
) illustrates that even patients in the lowest risk
roup are still subject to relapses and late deaths from
cancer, particularly after the 5th year of follow-up.
C-based riskmodel incorporating Ki67 andHER2 al-ig. 4E) and DSS (Fig. 4F), although these differences
rrower than those achieved by the gene expression–
model.
ssion
vious studies have established that intrinsic biologi-
natures are present and have prognostic significance
ast cancer cohorts from multiple different institu-
profiled with several gene expression microarray
rms (21–24). To identify these subtypes on standard
lin-fixed, paraffin-embedded pathology specimens,
veloped a qRT-PCR test based on a panel of 50 genes
he analysis reported here applied this test to a seriession that the ROR-T score produces the best prognos- of paraffin blocks with >15-year detailed follow-up.
-index estimates of RFS andDSS for different measures of hormone receptors and proliferation. The luminal and proliferationmeasures are themeans
bed in Supplementary Materials and Methods. P values were
ement (P < 0.05) in C-index relative to clinical quantitative ER by
.05) in C-index relative to visual quantitative Ki67 index.
Clinical Cancer Research


























Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-1282 ereas previously assessed cohorts consisted mainly of
sk women receiving no adjuvant systemic therapy, or
eterogeneously treated, the cases in the current study
women with ER+ breast cancer who received endo-
therapy as their sole adjuvant treatment, a group of
ular clinical importance and contemporary relevance.
s analysis, we sought to compare different technolo-
g the best-performing model, ROR-PT values are related to actual 10-year e
nfidence interval). C and D, Kaplan-Meier survival analysis of the size and
tion provided by a model of IHC subtype and tumor size. D and F, breastr predicting long-term outcomes for such patients. In
tudy cohort, patients were diagnosed with N+ or
r-risk N0 disease. Only 8% of the N0 population







on February 27, clincancerres.aacrjournals.org wnloaded from (Table S2). Under the current standard of care in
countries, the majority of these patients would now
ated with adjuvant chemotherapy (25) and extended
rine therapy. Using a series of fixed models trained in
endent data sets, we compared a standard approach
clinicopathologic information (Adjuvant! Online)
our published luminal B discriminator based on
obabilities using a Cox proportional hazard model (dotted lines are
ation weighted ROR (ROR-PT) assignments. E and F, comparable
DSS (excludes two cases with unknown cause of death).Comparison of prognostic classifiers in N0 subjects. A, the C-index is used to compare accuracy of the prognostic classifiers (Supplementary
5). Asterisks denote significant improvement (P < 0.05) in C-index relative to the clinical model (Adjuvant!) (*), or relative to the IHC-T model (**).
PAM50 in ER-Positive Breast Cancerand HER2 IHC additionally weighted for T stage
T), and with PAM50 gene expression–based ROR
ls weighted for T stage (ROR-T and ROR-PT). In
tients, the ROR-PT approach was the most accurate
Clin Cancer Res; 16(21) November 1, 2010 5229
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Published OnlineFirst September 13, 2010; DOI: 10.1158/1078-0432.CCR-10-1282 as able to identify patients in whom 5 years of
ifen may be adequate treatment based on the very
te relapse rate in the 5- to 10-year window (Fig.
n N+ disease, the PAM50 approach represents an
ce in prognostication, but late relapses and deaths
seen even in the lowest risk group identified using
st ROR model. Unlike in N0 disease, proliferation
ure weighting did not improve the C-index in N+
e.
this cohort, detailed centrally determined IHC anal-
Comparison of prognostic classifiers in N subjects. A, C-index compariso
proportional hazard model relating the best-performing model (ROR-T) to a
OR-T assignments for RFS (C) and DFS (D). E and F, comparable informave previously been done and published (6, 10–13,
-index, Kaplan-Meier, and Cox model analyses show
HC approaches do work and provide significant





ancer Res; 16(21) November 1, 2010
Research. 
on February 27, clincancerres.aacrjournals.org wnloaded from e superior in terms of adding significant additional
ation and in their capacity to identify a particularly
sk group of women.
view these PAM50 models, derived from archival
alin-fixed RNA, as a potential replacement for
, hormone receptor–, Ki67-, and HER2-based prog-
models, but not as a replacement for pathologic
(as tumor size and nodal status remain independent
tors in multivariable models that include PAM50-
prognostic information). One weakness of our
e accuracy of prognostic classifiers as described in Fig. 3.
0-year event probabilities. C and D, Kaplan-Meier survival analysis
s provided by a model of IHC subtype and tumor size.n et al.ach is that our current accounting for pathologic
is oversimplified due to the limited stage distribu-
and clinical information in our training sets. We an-
the data as either N0 or N+, and accounted for T
Clinical Cancer Research
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aim is to integrate the PAM50 data into the Ad-
t! Online approach (27) to more completely ac-
for the prognostic influence of pathologic stage.
hieve this, we would need to construct a training
at adequately includes all the five categories of T
nd four categories of N stage used in Adjuvant!
e to gauge the prognostic weight of these patho-
stage categories in the setting of PAM50 informa-
Additionally, incorporation of all IHC data as
uous variables in a combined model may improve
ognostic value. The current series contains suffi-
detailed clinical and IHC information to contrib-
such detailed comparisons as a training set
ing further validation.
additional caveat to our study is that the popula-
as strongly biased toward higher-risk breast cancers
likely underestimates of the number of patients in
oader, N0 population for whom adjuvant tamoxi-
ould represent adequate treatment. The current gen-
n of adjuvant aromatase inhibitor trials would be
propriate setting to address the value of our ap-
h further. We accept the possibility that a better
l using Ki67 at a different cut point could be devel-
However, because we were focused on comparing
models, we used our published approach. Further
on the Ki67 model and cut-point optimization will
e independent data sets.
omparison with other signatures such as the recur-
score and genomic grade index (1, 28, 29), the
0 has the potential advantage of discriminating
isk patients into luminal B, HER2-enriched, and
like subtypes, who are likely to respond differently
main systemic therapy options (endocrine, anti-
, and anthracycline versus nonanthracycline versus
chemotherapy regimens). The assay requires nei-
rozen tissue (30) nor manual microdissection of
ctions (1), and can be readily applied to standard
in blocks including archival tissues from clinical
Currently available assays such as Mammaprint
nd Oncotype DX (32) were optimized to recognize
ularly low-risk patients from among a N0 early-stage
ation who did not receive chemotherapy. Because
sic subtyping is designed to identify discriminative
ical features of breast cancer, rather than being de-
around clinical outcome in a specific population,
proach is particularly likely to extrapolate well onto
patient cohorts (33). The current study shows the
of PAM50 to recognize a very low-risk prognostic
among women receiving tamoxifen and no chemo-
y, similar to the Oncotype DX assay (34, 35). A di-
mparison of different expression profile approaches
ecome possible in the future through a reanalysis of
ts with the PAM50 that have already been analyzed
cotype DX, because both assays can be applied to
me source material.
r inability to identify a group of patients with N+ dis-







on February 27, clincancerres.aacrjournals.org wnloaded from f the recent findings from the Southwest Oncology
, who also found that a molecular signature for
outcome in N0 disease failed in N+ disease in this
(35). It would be relevant to study a series of pa-
treated with extended adjuvant aromatase inhibi-
erapy, who will have even lower residual risk, as
of the patients in the low-risk N+ group may sim-
quire longer treatment with modern endocrine
y rather than chemotherapy. The development of
pproaches for defining prognosis in N+ disease is
arranted. We have already established the preop-
e endocrine prognostic index, which showed that
n endocrine treatment” Ki67 value is more effec-
an baseline Ki67 for the identification of patients
clinical stage II and III disease who have excellent
erm outcomes after neoadjuvant endocrine therapy
A comparison between Ki67 and the PAM50-based
eration signature in the neoadjuvant endocrine
y setting is therefore one logical next step. The ap-
ility of this test to formalin-fixed, paraffin-embedded
s will make possible its use on large clinical trial
es that address this issue (37). The results of our
highlight the feasibility of measuring multigene
sion panels on such series as a means for showing
l utility using a method readily applicable to pro-
ve clinical samples that provides more prognostic
ation than clinical or standard IHC approaches.
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